Stendra is owned by Metuchen Pharms.
Stendra contains Avanafil.
Stendra has a total of 2 drug patents out of which 0 drug patents have expired.
Stendra was authorised for market use on 27 April, 2012.
Stendra is available in tablet;oral dosage forms.
Stendra can be used as treatment of erectile dysfunction.
The generics of Stendra are possible to be released after 18 October, 2025.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US6656935||METUCHEN PHARMS||Aromatic nitrogen-containing 6-membered cyclic compounds|| |
(2 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7501409||METUCHEN PHARMS||Preparations for oral administration|| |
(a month from now)
|M (M)||Oct 18, 2025|
Drugs and Companies using AVANAFIL ingredient
Market Authorisation Date: 27 April, 2012
Treatment: Treatment of erectile dysfunction
Korea, Republic of
Taiwan, Province of China
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic